Kevin Hoagland-Hanson

Partner

202.434.5111

Kevin Hoagland-Hanson focuses his practice on patent litigation and related disputes, primarily in the pharmaceutical and biotechnology industries. Kevin has represented clients at every stage of litigation, from complaint through trial. Kevin has experience in Hatch-Waxman litigation and damages cases, involving both small-molecule and biologic drugs. Kevin has also represented clients in appellate proceedings before the United States Court of Appeals for the Federal Circuit.

Kevin joined Williams & Connolly in 2017. He is a member of the firm’s Hiring Committee.

Prior to joining the firm, Kevin clerked for Judge Anthony Scirica of the United States Court of Appeals for the Third Circuit and Judge Jan E. DuBois of the United States District Court for the Eastern District of Pennsylvania. Kevin received his law degree in 2015 from the University of Pennsylvania, where he was an editor of the University of Pennsylvania Law Review, and his B.A. in 2009 from Bowdoin College.

Though all cases vary and none is predictive, Kevin’s experience includes:

Representation of AstraZeneca in Hatch-Waxman litigation in the United States District Court for the Northern District of West Virginia and on appeal to the United States Court of Appeals for the Federal Circuit, relating to Mylan’s application to market a generic version of AstraZeneca’s Symbicort product. Following a six-day bench trial, the Court ruled in favor of AstraZeneca as to all claims, rejecting Mylan’s argument that the asserted claims were invalid.
Representation of AstraZeneca in litigation brought by Bristol-Myers Squibb in the District of Delaware relating to AstraZeneca’s cancer immunotherapy product Imfinzi®.
Representation of Pfizer in Hatch-Waxman litigation concerning Pfizer’s Ibrance product.
Representation of Novartis in a Hatch-Waxman patent matter relating to Xiidra®.
Representation of defendant AstraZeneca in brand v. brand patent litigation involving Calquence® (acalabrutinib).

“Rising Star,” Managing IP, 2024-2025

News & Insights

Press Releases